CJC-1295 & Ipamorelin vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295 & Ipamorelin
The most popular growth hormone secretagogue combination. CJC-1295 (a GHRH analog) and Ipamorelin (a ghrelin mimetic) work synergistically to stimulate natural growth hormone release with potentially greater effects than either peptide alone.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 & Ipamorelin | Retatrutide |
|---|---|---|
| Mechanism | CJC-1295 binds to GHRH receptors to sustain GH signaling and extend the half-life of growth hormone release. Ipamorelin triggers strong GH pulses by binding to ghrelin receptors. Together, they create both sustained and pulsatile GH release patterns that more closely mimic natural physiology. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | CJC-1295 (no DAC/Mod GRF 1-29): 100-300mcg combined with Ipamorelin 200-300mcg, administered 1-3 times daily. Best results when administered fasted or before sleep. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Subcutaneous injection. Often administered before bedtime to enhance natural nighttime GH release, or in the morning fasted. The combination is typically pre-mixed or injected simultaneously. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Water retention, tingling in extremities, mild headaches, lightheadedness, or increased hunger. Generally well-tolerated with minimal effect on cortisol or prolactin. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |
What They Have in Common
Both CJC-1295 & Ipamorelin and Retatrutide are commonly used for: